Vigil Neuroscience, Inc. (NASDAQ:VIGL Free Report) Research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Vigil Neuroscience in a research report issued on Wednesday, March 27th. HC Wainwright analyst A. Fein expects that the company will earn ($0.58) per share for the quarter. HC Wainwright has a Buy rating and a $24.00 price objective on the stock. The consensus estimate for Vigil Neurosciences current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vigil Neurosciences Q3 2024 earnings at ($0.58) EPS.

Separately, Morgan Stanley cut Vigil Neuroscience from an equal weight rating to an underweight rating and decreased their price objective for the company from $13.00 to $4.00 in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $17.40.

NASDAQ:VIGL opened at $3.41 on Thursday. The stocks fifty day moving average price is $3.06 and its two-hundred day moving average price is $4.32. Vigil Neuroscience has a 52-week low of $2.53 and a 52-week high of $11.11. The company has a market cap of $122.35 million, a price-to-earnings ratio of -1.60 and a beta of 1.80.

Several hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Vigil Neuroscience during the fourth quarter worth approximately $27,000. Royal Bank of Canada acquired a new stake in Vigil Neuroscience during the second quarter worth approximately $33,000. California State Teachers Retirement System acquired a new stake in Vigil Neuroscience during the second quarter worth approximately $50,000. Wells Fargo & Company MN lifted its position in Vigil Neuroscience by 6,988.4% during the second quarter. Wells Fargo & Company MN now owns 6,096 shares of the companys stock worth $57,000 after acquiring an additional 6,010 shares during the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Vigil Neuroscience during the second quarter worth approximately $86,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

(Get Free Report)

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share - Defense World